# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.07) per share. This is a 70.83 percent increase over losses of $(...
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0....
During the session on Thursday, 461 stocks hit new 52-week lows.
Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and maintains $5 price target.
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0....